Virpax Pharmaceuticals (NASDAQ: VRPX) +100%; adds to yesterday's gain.

AzurRx BioPharma (NASDAQ: AZRX) +35%; today announced positive topline results from its Phase 2 Combination Trial evaluating MS1819 in combination with the current standard of care, porcine-derived pancreatic enzyme replacement therapy (PERT), for the treatment of severe exocrine pancreatic insufficiency in patients with cystic fibrosis (CF).

TD Holdings, Inc. (NASDAQ: GLG) +25%; today announced its financial results for the second quarter ended June 30, 2021.

Grove Inc (NASDAQ: GRVI) +8%; Alfi, Inc. (NASDAQ: ALF) ("Alfi" or the "Company"), an AI enterprise SaaS platform company powering computer vision with machine learning models to allow content publishers and brand owners to deliver interactive, intelligent information without violating user privacy, and Grove, Inc. (NASDAQ: GRVI) ("Grove" or the "Company"), redefining the way hemp is bought, produced, and sold, today announced they have partnered to launch a campaign aimed at building consumer awareness of Grove's Cannabidiol ("CBD") products for the botanical, beauty care, pet care and functional food sector.

Tilray, Inc. (NASDAQ: TLRY) +7%; acquired the majority of the outstanding senior secured convertible notes (the “Notes”) of MedMen that were originally held by certain funds affiliated with Gotham Green Partners, LLC and other funds (collectively, “GGP”). The acquisition provides Tilray with a path, subject to necessary regulatory approvals, to obtain a significant equity position in MedMen through conversion of the Notes and exercise of associated warrants.

Lowe's Cos. (NYSE: LOW) +4%; reported Q2 EPS of $4.25, $0.28 better than the analyst estimate of $3.97. Revenue for the quarter came in at $27.6 billion versus the consensus estimate of $26.73 billion. GUIDANCE: Lowe's Cos. sees FY2021 revenue of $92 billion, versus the consensus of $91.5 billion.

Children's Place (NASDAQ: PLCE) -7.8%; reported Q2 EPS of $1.71, $1.40 better than the analyst estimate of $0.31. Revenue for the quarter came in at $413.9 million versus the consensus estimate of $417.31 million.

Cree (NASDAQ: CREE) -7%; reported Q4 EPS of ($0.23), $0.01 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $145.8 million versus the consensus estimate of $145.17 million. GUIDANCE: Cree sees Q1 2022 EPS of ($0.21)-($0.25), versus the consensus of ($0.23). Cree sees Q1 2022 revenue of $144-154 million, versus the consensus of $153.4 million.